The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.
 
Ronan Flippot
Honoraria - Astellas Oncology; Bristol-Myers Squibb; Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA; Pfizer
Consulting or Advisory Role - Ipsen; Janssen; Merck KGaA
 
Tugce Telli
No Relationships to Disclose
 
Maud Velev
No Relationships to Disclose
 
Aude Flechon
Honoraria - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; Ipsen; Janssen-Cilag; MSD Oncology; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Lea Turpin
No Relationships to Disclose
 
Andre M. Bergman
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Sanofi
Research Funding - Astellas Pharma; Bayer
Travel, Accommodations, Expenses - Bayer
 
Fabio Turco
No Relationships to Disclose
 
Wolfgang Peter Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - Bayer; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Anne Laure Giraudet
No Relationships to Disclose
 
Françoise Montravers
No Relationships to Disclose
 
Wouter V. Vogel
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer (Inst); BMS (Inst); ESMO; German-speaking European School of Oncology (DESO); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Radiotelevisione Svizzera Italiana (RSI); Silvio Grasso Consulting (Inst); Swiss Academy of Multidisciplinary oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - ProteoMediX
 
Simona Berardi
No Relationships to Disclose
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - Aktis Oncology; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers
 
David Kryza
No Relationships to Disclose
 
Gaetano Paone
No Relationships to Disclose
 
Camilo Garcia
No Relationships to Disclose
 
Stéphanie Foulon
No Relationships to Disclose
 
Arnaud Pages
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); ESSA (Inst); Janssen Oncology (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD